Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.64 |
| ▸ | GHSR | Q92847 | 7/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30128024 | 0.88 | SLC15A2 (0.55) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL28027302 | 0.85 | SLC15A2 (0.71) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL30409074 | 0.85 | SLC15A2 (0.71) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL17585533 | 0.83 | SLC15A2 (0.58) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL29867441 | 0.82 | SLC15A2 (0.62) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL27706632 | 0.81 | SLC15A2 (0.74) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL30911281 | 0.81 | SLC15A2 (0.74) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL24725154 | 0.80 | CYP3A4 (0.43) | SLC15A2CYP3A4SLC7A5 | |
| SCHEMBL29774690 | 0.79 | SLC15A2 (0.72) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL29774683 | 0.79 | SLC15A2 (0.72) | SLC15A2GHSRCPB2CYP3A4SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250432-A1 | siRNA-Copolymer Compositions And Methods Of Use For Treatment Of Liver Cancer | SIRNAOMICS, INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250432-A1 | siRNA-Copolymer Compositions And Methods Of Use For Treatment Of Liver Cancer | HDGF, HDGFL3, HCCS | SLC15A2 1311/4885GHSR 3317/4885CPB2 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.